Page 32 - Haematologica Vol. 107 - September 2022
P. 32
REVIEW ARTICLE - ITP: diagnosis and second-line treatment J.B. Bussel and C.A. Garcia
general practice, it is usually reserved for patients who have failed to respond to thrombopoietin agents.
With many second-line agents, there are various treat-
ment options and courses depending on individual re- sponses, relapses and potential complications with each agent, as demonstrated in Figure 2.
Figure 2. Second-line treatment options for immune thrombocytopenia and possible treatment courses. TPO: thrombopoietin; R1, R2, R3, R4: first, second, third and fourth weekly dose of rituximab; COVID: coronavirus disease 2019; ITP: immune thrombocytopenia; BID: bis in die.
Haematologica | 107 September 2022
2031
